HRK (harakiri, BCL2 interacting protein) is a pro-apoptotic BCL2 family member that promotes programmed cell death through mitochondrial-dependent mechanisms. HRK functions by facilitating the release of cytochrome c from mitochondria and regulating protein complex assembly at the mitochondrion, thereby activating the intrinsic apoptotic pathway. The protein interacts with anti-apoptotic BCL2 family members to tip the balance toward cell death, making it a critical regulator of cellular homeostasis. While the provided abstracts do not directly address HRK's role in specific diseases, HRK's pro-apoptotic function suggests potential relevance to conditions characterized by insufficient cell death, such as cancer and neurological disorders. Cancer cells frequently develop mechanisms to evade apoptosis, and dysregulation of pro-apoptotic genes like HRK may contribute to tumorigenesis. Conversely, excessive HRK activity could contribute to degenerative diseases involving inappropriate cell death. Clinically, HRK represents a potential therapeutic target for restoring apoptosis in cancer cells. However, specific information regarding HRK mutations, expression patterns in disease states, or clinical applications is not available in the provided literature. Further functional studies are needed to establish HRK's disease associations and therapeutic potential.